Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -4 of 4
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/30/2008
 
First Published:
8/14/2007
1.
Phase III Randomized Study of Dalteparin for Venous Thromboembolism Prophylaxis in Patients With Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Active
18 and over
Other, Pharmaceutical / Industry
WCTU-FRAGMATIC
Velindre-FRAGMATIC, WCTU-02, EU-20753, WCTU-02, PFIZER-WCTU-02, WCTU-FRAGMATIC, EUDRACT-2005-002438-37, ISRCTN80812769, NCT00519805
Last Modified:
1/13/2009
 
First Published:
4/17/2008
2.
Phase III Randomized Study of Gemcitabine Hydrochloride With or Without Capecitabine With or Without Preventive Anticoagulation Comprising Dalteparin in Patients With Metastatic Pancreatic Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Supportive care, Treatment
Active
18 to 80
Other, Pharmaceutical / Industry
GERCOR-PAM07-D07-2
GERCOR-PAM07-D07-2, EUDRACT 2007-002115-59, EU-20837, PFIZER-GERCOR-PAM07-D07-2, NCT00662688
Last Modified:
4/25/2007
 
First Published:
4/13/2007
3.
Phase II Randomized Study of Gemcitabine Hydrochloride With Versus Without Dalteparin in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Supportive care, Treatment
Active
18 and over
Other, Pharmaceutical / Industry
PRH-HCTU-FRAGEM
PRH-HCTU-FRAGEM-V-12.1, CTA-MF8000/13558, EU-20721, LILLY-PRH-HCTU-FRAGEM, FRAGEM, ISRCTN76464767, NCT00462852
4.
DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Supportive care
Active
30 and over
Other
2004-0743
NCT00525057
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute